C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

Απλή σελίδα τεκμηρίου
dc.contributor.authorLengyel, E.en
dc.contributor.authorPrechtel, D.en
dc.contributor.authorResau, J. H.en
dc.contributor.authorGauger, K.en
dc.contributor.authorWelk, A.en
dc.contributor.authorLindemann, K.en
dc.contributor.authorSalanti, G.en
dc.contributor.authorRichter, T.en
dc.contributor.authorKnudsen, B.en
dc.contributor.authorVande Woude, G. F.en
dc.contributor.authorHarbeck, N.en
dc.date.accessioned2015-11-24T19:30:09Z
dc.date.available2015-11-24T19:30:09Z
dc.identifier.issn0020-7136-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23030
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBreast Neoplasms/drug therapy/*metabolism/*pathologyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectFibrocystic Breast Disease/drug therapy/metabolism/pathologyen
dc.subjectHepatocyte Growth Factor/metabolismen
dc.subjectHumansen
dc.subjectHyperplasia/drug therapy/metabolism/pathologyen
dc.subjectLigandsen
dc.subjectLymph Nodes/pathologyen
dc.subjectLymphatic Metastasis/*pathologyen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPilot Projectsen
dc.subjectProto-Oncogene Proteins c-met/*metabolismen
dc.subjectReceptor, erbB-2/*metabolismen
dc.subjectReceptors, Estrogen/metabolismen
dc.subjectReceptors, Progesterone/metabolismen
dc.subjectRisk Factorsen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titleC-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neuen
heal.abstractReceptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression. Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease-free survival in patients with c-Met overexpressing tumors was 8 months compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1002/ijc.20598-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15455388-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/ijc.20598/asset/20598_ftp.pdf?v=1&t=h0dok7re&s=254db45fd575faa12905ce0be944e6cd20b0278f-
heal.journalNameInt J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ